Gapping up
In reaction to strong earnings/guidance:
- RPAY +11.4%, YY +8.8%, COUP +6.8%, DBI +4.9%, TERP +4.1%, HUYA +2.1%, PLCE +1.8%, TME +1.2%
Other news:
- ENLC +95.2% (announces 30% reduction to 2020 capital expenditures and prioritizes financial flexibility)
- BNTX +63.7% (BioNTech and Pfizer (PFE) to to co-develop potential COVID-19 vaccine)
- CODX +46.8% (FDA changes policy to allow rapid domestic expansion of co-diagnostics COVID-19 test)
- AIMT +22% (up in sympathy on negative DBVT news)
- MNK +17.2% (completes rolling submission of New Drug Application for terlipressin for the treatment of patients with hepatorenal syndrome type 1)
- ABEO +17.2% (announces first patient in the pivotal phase III VIITAL study evaluating EB-101, the Company's gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa)
- REGN +10% (announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected)
- REGI +9.9% (files mixed securities shelf offering)
- HOLX +8.5% (molecular test for the novel coronavirus, SARS-CoV-2, receives fda emergency use authorization)
- TMO +7.7% (Mad Money mention)
- WTI +7.3% (announces that it has reduced its capital expenditure budget for 2020 and that it has added natural gas costless collars to its hedging portfolio)
- GOL +6.5% (will reduce total flight capacity by 60-70% until mid-June)
- STOR +5.7% (plans to limit investment activity in the short run)
- JD +5% (announces $2 bln share repurchase program)
- CZR +4.4% (has fully drawn on revolving credit as a precautionary measure)
- AMZN +4.2% (announces it's opening 100,000 new full and part-time positions)
- UPS +3.6% (to support coronavirus test kit deliveries)
- TTD +3.4% (expands relationship with Samba TV)
- AZN +2.5% (confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer)
Analyst comments:
- SQ +4.2% (upgraded to Outperform from Market Perform at Cowen)
- WMT +4% (upgraded to Outperform from Perform at Oppenheimer)
- PG +3.3% (upgraded to Buy from Hold at Deutsche Bank)
- PEP +3% (upgraded to Outperform from In-line at Evercore ISI)
- CHKP +2.7% (upgraded to Buy from Hold at SunTrust)
- CTXS +2.6% (upgraded to Outperform from Mkt Perform at Raymond James)
- BAC +2.3% (upgraded to Outperform from Neutral at Robert W. Baird)
- EA +1.7% (upgraded to Buy from Neutral at MKM Partners)